Breakdown | ||||
Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.81T | 1.75T | 1.88T | 1.61T | 1.21T | Gross Profit |
388.29B | 370.80B | 381.49B | 378.74B | 293.84B | EBIT |
92.94B | 74.12B | 129.00B | 147.31B | 78.07B | EBITDA |
173.69B | 181.15B | 182.81B | 216.99B | 157.75B | Net Income Common Stockholders |
32.24B | 50.00B | 82.94B | 109.99B | 57.87B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
170.62B | 210.29B | 262.72B | 224.65B | 223.16B | Total Assets |
2.15T | 2.22T | 2.07T | 1.93T | 1.56T | Total Debt |
737.98B | 756.76B | 738.25B | 666.09B | 510.22B | Net Debt |
567.36B | 546.47B | 551.94B | 484.93B | 314.23B | Total Liabilities |
1.18T | 1.23T | 1.18T | 1.13T | 875.97B | Stockholders Equity |
848.28B | 862.85B | 786.83B | 712.65B | 607.92B |
Cash Flow | Free Cash Flow | |||
79.29B | 7.35B | -36.62B | -23.63B | 97.74B | Operating Cash Flow |
200.50B | 161.34B | 101.24B | 92.58B | 174.32B | Investing Cash Flow |
-165.01B | -123.94B | -106.34B | -205.23B | -77.56B | Financing Cash Flow |
-74.44B | -26.02B | 2.54B | 89.22B | -68.96B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | ¥321.11B | 6.66 | 13.58% | 4.80% | 5.10% | -8.07% | |
78 Outperform | ¥638.76B | 17.58 | 13.21% | 2.03% | 7.23% | 8.93% | |
73 Outperform | $244.55B | 9.65 | 5.38% | 3.20% | 5.89% | 11.92% | |
71 Outperform | ¥418.93B | 9.43 | 6.78% | 4.32% | -4.90% | 20.59% | |
68 Neutral | ¥612.23B | 18.88 | 3.69% | 4.46% | 3.40% | -35.14% | |
63 Neutral | $909.03B | ― | -4.41% | 4.59% | 1.96% | -399.31% | |
51 Neutral | $2.04B | -1.15 | -21.37% | 3.64% | 2.88% | -30.57% |
Mitsui Chemicals is considering splitting off its Basic & Green Materials business to enhance its business structure and promote green initiatives. This strategic move aims to foster collaboration with other companies, improve competitiveness, and support Japan’s industrial competitiveness by creating a strong, independent green chemicals business entity by 2027.
The most recent analyst rating on (JP:4183) stock is a Sell with a Yen3650.00 price target. To see the full list of analyst forecasts on Mitsui Chemicals stock, see the JP:4183 Stock Forecast page.
Mitsui Chemicals announced a decline in its FY2024 non-consolidated financial results compared to the previous fiscal year. The company reported a decrease in ordinary and net income, primarily due to reduced operating income and dividend income, impacting its financial performance and potentially affecting stakeholder confidence.
The most recent analyst rating on (JP:4183) stock is a Sell with a Yen3650.00 price target. To see the full list of analyst forecasts on Mitsui Chemicals stock, see the JP:4183 Stock Forecast page.
Mitsui Chemicals reported a shortfall in its FY2024 financial results compared to its previous forecasts. The decline was primarily due to decreased sales in the ICT Solutions segment and an impairment loss in the Life & Healthcare Solutions segment, along with increased income tax expenses. Despite these challenges, the company maintained its dividend forecast.
The most recent analyst rating on (JP:4183) stock is a Sell with a Yen3650.00 price target. To see the full list of analyst forecasts on Mitsui Chemicals stock, see the JP:4183 Stock Forecast page.
Mitsui Chemicals reported a 5% increase in operating income before special items for FY2024, reaching 101.0 billion yen, driven by growth in specialty chemicals and successful sales price revisions in basic materials. Despite challenges such as an ethylene plant failure in Osaka, the company managed to offset losses through strategic business restructuring, indicating a strong market position and resilience.
The most recent analyst rating on (JP:4183) stock is a Sell with a Yen3650.00 price target. To see the full list of analyst forecasts on Mitsui Chemicals stock, see the JP:4183 Stock Forecast page.
Mitsui Chemicals reported its consolidated financial results for FY2024, showing a slight increase in sales revenue and operating income. Despite challenges in certain segments, the company saw growth in Life & Healthcare Solutions and Mobility Solutions. The organizational reforms and segment revisions implemented in April 2024 are expected to impact future performance positively. However, the company faced a decrease in net income and cash flow challenges, indicating a need for strategic adjustments to maintain financial stability.
The most recent analyst rating on (JP:4183) stock is a Sell with a Yen3650.00 price target. To see the full list of analyst forecasts on Mitsui Chemicals stock, see the JP:4183 Stock Forecast page.
Mitsui Chemicals, Inc. announced the completion of its tender offer to acquire common shares of DNA Chip Research Inc. The acquisition, resolved in February 2025, involved purchasing up to 5,823,062 shares, with a minimum threshold of 3,119,000 shares. This strategic move is expected to enhance Mitsui Chemicals’ capabilities and market positioning in the biotechnology sector.
Mitsui Chemicals has announced the abolition of its Senior Advisor and Advisor system, aiming to improve management transparency and effectiveness. Additionally, the company will change the chairperson of its Nomination Committee to an independent outside director, enhancing the fairness and objectivity of its nomination process.
Mitsui Chemicals has announced the establishment of a Restricted Stock Incentive Plan aimed at its Employee Shareholding Association. This plan involves the disposal of 1,245,000 treasury shares as restricted stock to incentivize employees, aligning their interests with shareholders and promoting long-term corporate value. The initiative is designed to enhance asset-building opportunities for employees while fostering shared value creation with stakeholders.